Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

Burman, Joachim, Iacobaeus, Ellen, Svenningsson, Anders, Lycke, Jan, Gunnarsson, Martin, Nilsson, Petra, Vrethem, Magnus, Fredrikson, Sten, Martin, Claes, Sandstedt, Anna, Uggla, Bertil, Lenhoff, Stig, Johansson, Jan-Erik, Isaksson, Cecilia, Hägglund, Hans, Carlson, Kristina, Fagius, Jan · 2014 · Journal of Neurology, Neurosurgery & Psychiatry

Abstract

BACKGROUND: Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. METHODS: Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. RESULTS: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). CONCLUSIONS: HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2013-307207

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Burman, J., Iacobaeus, E., Svenningsson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A., Uggla, B., Lenhoff, S., Johansson, J.-E., Isaksson, C., Hägglund, H., Carlson, K., & Fagius, J.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2014-02-19
Volume
85
Issue
10
Pages
1116-1121
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W2165405170
Cited by
166
References
1
FWCI
13.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. https://app.cochat.ai/papers/10.1136/jnnp-2013-307207
The paper
Burman, J., Iacobaeus, E., Svenningsson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A., Uggla, B., Lenhoff, S., Johansson, J.-E., Isaksson, C., Hägglund, H., Carlson, K., & Fagius, J. (2014). Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2013-307207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.